Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to lower patients with exacerbations treated with oral steroids compared with current best practice (moderate certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).